Prelude Therapeutics (PRLD) investor relations material

Executive summary

• Focused on precision oncology with a diverse pipeline including kinase inhibitors, targeted protein degraders, and degrader antibody conjugates.

• Lead JAK2V617F inhibitor program (PRT12396) advanced to Phase 1 in PV and MF patients, with an exclusive option agreement with Incyte for up to $910M in milestones and royalties.

• IND filing for first-in-class oral KAT6A degrader (PRT13722) expected by mid-2026, with Phase 1 in ER+ breast cancer anticipated in 2H 2026.

• Paused SMARCA2 degrader clinical program to prioritize JAK2V617F and KAT6A programs.

• Appointed Charles Morris, M.D. as Chief Medical Officer.

Financial highlights

• Revenue of $4.6M for Q1 2026, entirely from the Incyte option agreement, compared to $0 in Q1 2025.

• Net loss of $10.4M for Q1 2026 ($0.13 per share), down from $32.1M ($0.42 per share) in Q1 2025.

• Research and development expenses decreased to $13.6M from $28.8M year-over-year, mainly due to pausing SMARCA2 trials and lower stock-based compensation.

• General and administrative expenses decreased to $5.2M from $5.8M year-over-year.

• Cash, cash equivalents, restricted cash, and marketable securities totaled $84.8M as of March 31, 2026.

Outlook and guidance

• Cash runway expected to fund operations into Q2 2028 after $90M equity and warrant offering in April 2026, with net proceeds of $85.5M.

• Anticipates continued operating losses as product candidates advance through development and clinical trials.

• Expects to file IND for KAT6A degrader in mid-2026 and initiate Phase 1 in the second half of 2026.

• Continued advancement of mCALR program and next-generation DACs.